AU2018380979B2 - Use of FcRn antagonists for treatment of generalized myasthenia gravis - Google Patents

Use of FcRn antagonists for treatment of generalized myasthenia gravis Download PDF

Info

Publication number
AU2018380979B2
AU2018380979B2 AU2018380979A AU2018380979A AU2018380979B2 AU 2018380979 B2 AU2018380979 B2 AU 2018380979B2 AU 2018380979 A AU2018380979 A AU 2018380979A AU 2018380979 A AU2018380979 A AU 2018380979A AU 2018380979 B2 AU2018380979 B2 AU 2018380979B2
Authority
AU
Australia
Prior art keywords
certain embodiments
subject
fcrn antagonist
treatment
achr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018380979A
Other languages
English (en)
Other versions
AU2018380979A1 (en
Inventor
Johannes De Haard
Torsten Dreier
Antonio Guglietta
Nicolas LEUPIN
Peter Ulrichts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2018380979A1 publication Critical patent/AU2018380979A1/en
Application granted granted Critical
Publication of AU2018380979B2 publication Critical patent/AU2018380979B2/en
Priority to AU2023229716A priority Critical patent/AU2023229716A1/en
Assigned to argenx BV reassignment argenx BV Request to Amend Deed and Register Assignors: ARGENX BVBA
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2018380979A 2017-12-08 2018-12-07 Use of FcRn antagonists for treatment of generalized myasthenia gravis Active AU2018380979B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023229716A AU2023229716A1 (en) 2017-12-08 2023-09-18 Use of FcRn antagonists for treatment of generalized myasthenia gravis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762596562P 2017-12-08 2017-12-08
US62/596,562 2017-12-08
PCT/EP2018/084034 WO2019110823A1 (en) 2017-12-08 2018-12-07 Use of fcrn antagonists for treatment of generalized myasthenia gravis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023229716A Division AU2023229716A1 (en) 2017-12-08 2023-09-18 Use of FcRn antagonists for treatment of generalized myasthenia gravis

Publications (2)

Publication Number Publication Date
AU2018380979A1 AU2018380979A1 (en) 2020-05-21
AU2018380979B2 true AU2018380979B2 (en) 2023-07-20

Family

ID=64901981

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018380979A Active AU2018380979B2 (en) 2017-12-08 2018-12-07 Use of FcRn antagonists for treatment of generalized myasthenia gravis
AU2023229716A Pending AU2023229716A1 (en) 2017-12-08 2023-09-18 Use of FcRn antagonists for treatment of generalized myasthenia gravis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023229716A Pending AU2023229716A1 (en) 2017-12-08 2023-09-18 Use of FcRn antagonists for treatment of generalized myasthenia gravis

Country Status (15)

Country Link
US (2) US12240875B2 (https=)
EP (1) EP3720877A1 (https=)
JP (2) JP7422659B2 (https=)
KR (1) KR102905500B1 (https=)
CN (1) CN111601820A (https=)
AU (2) AU2018380979B2 (https=)
BR (1) BR112020011483A2 (https=)
CA (1) CA3081144A1 (https=)
EA (1) EA202091410A1 (https=)
IL (1) IL274603A (https=)
MA (1) MA51032A (https=)
MX (1) MX2020005981A (https=)
NZ (1) NZ764034A (https=)
SG (1) SG11202003944WA (https=)
WO (1) WO2019110823A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0910622A2 (pt) * 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
CN112142843B (zh) 2013-12-24 2024-10-18 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
KR20250052465A (ko) 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
KR102921210B1 (ko) 2018-07-20 2026-01-30 모멘타 파머슈티컬스 인코포레이티드 Fcrn 항체 조성물
MA53903A (fr) * 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
CN114126647A (zh) 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
EP4004039A2 (en) * 2019-07-25 2022-06-01 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
KR102861118B1 (ko) 2020-08-03 2025-09-17 주식회사 엘지에너지솔루션 배터리 진단 디바이스, 배터리 팩, 배터리 시스템, 및 배터리 진단 방법
IL302516A (en) * 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
BR112023021046A2 (pt) * 2021-04-12 2023-12-19 Momenta Pharmaceuticals Inc Composições e métodos para tratamento de miastenia grave pediátrica
WO2023012515A2 (en) * 2021-08-02 2023-02-09 argenx BV Subcutaneous unit dosage forms
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
TW202428303A (zh) 2022-11-07 2024-07-16 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療原發性膜性腎病變之方法
KR20250109198A (ko) 2022-11-14 2025-07-16 아르젠엑스 비브이 Fcrn 길항제 분자 및 이의 사용 방법
AR131560A1 (es) 2023-01-06 2025-04-09 argenx BV Métodos para tratar pots mediante el uso de antagonistas de fcrn
IL322008A (en) 2023-01-12 2025-09-01 argenx BV Methods for treating primary Sjögren's syndrome with an FCRN antagonist
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン．ヴェー． 新生児型ｆｃ受容体に結合するポリペプチド
WO2024189430A1 (en) 2023-03-14 2024-09-19 argenx BV Methods for vaccination of a subject treated with an fcrn antagonist
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
GB202318512D0 (en) * 2023-12-04 2024-01-17 argenx BV Methods of determining potency
WO2025133694A1 (en) * 2023-12-20 2025-06-26 argenx BV Fcrn/hsa-binding molecules and methods of use
WO2025202714A1 (en) 2024-03-26 2025-10-02 argenx BV Methods for treating primary sjogren's syndrome using fcrn antagonists
WO2025224506A1 (en) 2024-04-22 2025-10-30 argenx BV Methods for reducing platelet degradation using fcrn antagonists
WO2025233685A1 (en) * 2024-05-10 2025-11-13 argenx BV Intravenous fcrn antagonist formulations and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053598A1 (en) * 2003-02-10 2005-03-10 Burke David J. Immunoglobulin formulation and method of preparation thereof
US20150218239A1 (en) * 2013-12-24 2015-08-06 Argen-X B.V. FCRN Antagonists and Methods of Use
WO2016142782A1 (en) * 2015-03-09 2016-09-15 Argen-X N.V. Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1323346B1 (en) 1995-01-17 2006-06-28 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
CA2467781C (en) 2000-11-20 2014-09-23 Canadian Blood Services Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
EP1588166A4 (en) 2003-01-09 2007-06-27 Macrogenics Inc VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004062619A2 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2006035600A1 (ja) 2004-09-30 2006-04-06 Brother Kogyo Kabushiki Kaisha 無線タグ通信装置、無線タグ、無線通信システム、及び無線通信方法
BRPI0606867A2 (pt) 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
CA2606378A1 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CN101835802B (zh) 2007-06-01 2014-04-09 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
US8108517B2 (en) 2007-11-27 2012-01-31 Umber Systems System and method for collecting, reporting and analyzing data on application-level activity and other user information on a mobile data network
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
BRPI0910622A2 (pt) 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
WO2010014909A1 (en) 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
MY173526A (en) 2009-03-25 2020-01-31 Genentech Inc Novel anti-?5?1 antibodies and uses thereof
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
MX2012007676A (es) 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
KR102014554B1 (ko) 2011-06-02 2019-08-26 다이액스 코포레이션 Fc 수용체 결합 단백질
CA2853637C (en) 2011-10-26 2023-04-04 Novartis Ag Anti-canine cd20 monoclonal antibodies and methods of use
EP2780463A4 (en) 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
US20150125449A1 (en) 2012-05-10 2015-05-07 Zymeworks Inc. Single-Arm Monovalent Antibody Constructs and Uses Thereof
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
EP3578660A1 (en) 2012-07-05 2019-12-11 F. Hoffmann-La Roche AG Expression and secretion system
ES2660912T3 (es) 2013-03-15 2018-03-26 Affibody Ab Nuevos polipéptidos
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
JP6620094B2 (ja) 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答を調節するための組成物および方法
SI3193930T1 (sl) 2014-09-17 2019-10-30 Affibody Ab Novi polipeptidi
KR20250052465A (ko) 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
ES2956662T3 (es) 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
JP7118884B2 (ja) 2015-07-17 2022-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3032415A1 (en) 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
EP3866785A1 (en) 2018-10-15 2021-08-25 Merck Patent GmbH Combination therapy utilizing dna alkylating agents and atr inhibitors
US20220002402A1 (en) 2018-11-06 2022-01-06 Immunovant Sciences Gmbh Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2020236695A1 (en) 2019-05-17 2020-11-26 Alexion Pharmaceuticals, Inc. Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases
CN114126647A (zh) 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
EP4007605A4 (en) 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
IL302516A (en) 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
WO2023012515A2 (en) 2021-08-02 2023-02-09 argenx BV Subcutaneous unit dosage forms
JP2025504815A (ja) 2022-01-17 2025-02-19 アルジェニクス ビーブイ 自己抗体媒介性疾患を有する患者を治療するための方法
KR20240151809A (ko) 2022-02-21 2024-10-18 아르젠엑스 비브이 Fcrn 길항제를 사용하여 근염을 치료하는 방법
IL316524A (en) 2022-04-26 2024-12-01 argenx BV Methods for treating bullous pemphigoid using FCRN antagonists
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
EP4615481A1 (en) 2022-11-07 2025-09-17 argenx BV Methods for treating lupus nephritis using fcrn antagonists
TW202428303A (zh) 2022-11-07 2024-07-16 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療原發性膜性腎病變之方法
KR20250109198A (ko) 2022-11-14 2025-07-16 아르젠엑스 비브이 Fcrn 길항제 분자 및 이의 사용 방법
AR131560A1 (es) 2023-01-06 2025-04-09 argenx BV Métodos para tratar pots mediante el uso de antagonistas de fcrn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053598A1 (en) * 2003-02-10 2005-03-10 Burke David J. Immunoglobulin formulation and method of preparation thereof
US20150218239A1 (en) * 2013-12-24 2015-08-06 Argen-X B.V. FCRN Antagonists and Methods of Use
WO2016142782A1 (en) * 2015-03-09 2016-09-15 Argen-X N.V. Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kang, J. et al., 'Rapid Formulation Development for Monoclonal Antibodies', BioProcess Int, (2016), vol. 14, no. 4, pages 40–44. *
Liu, L. et al., 'Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade', The Journal of immunology, (2007-04-15), vol. 178, no. 8, pages 5390 - 5398, doi: 10.4049/jimmunol.178.8.5390. *
Sockolosky, J & Szoka, F., 'The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy", Advanced Drug Delivery Reviews, (2015-02-19), vol. 91, pages 109 - 124, doi: 10.1016/J.ADDR.2015.02.005. *

Also Published As

Publication number Publication date
JP2021505603A (ja) 2021-02-18
US20250179133A1 (en) 2025-06-05
JP7422659B2 (ja) 2024-01-26
CA3081144A1 (en) 2019-06-13
JP2026048925A (ja) 2026-03-17
AU2018380979A1 (en) 2020-05-21
MX2020005981A (es) 2020-08-24
KR102905500B1 (ko) 2025-12-29
JP2024041928A (ja) 2024-03-27
US20190194277A1 (en) 2019-06-27
WO2019110823A1 (en) 2019-06-13
EA202091410A1 (ru) 2021-01-13
CN111601820A (zh) 2020-08-28
KR20200096786A (ko) 2020-08-13
NZ764034A (en) 2026-02-27
US12240875B2 (en) 2025-03-04
IL274603A (en) 2020-06-30
MA51032A (fr) 2021-03-17
EP3720877A1 (en) 2020-10-14
BR112020011483A2 (pt) 2020-11-24
AU2023229716A1 (en) 2023-10-05
SG11202003944WA (en) 2020-06-29

Similar Documents

Publication Publication Date Title
US20250179133A1 (en) Use of fcrn antagonists for treatment of generalized myasthenia gravis
JP7391132B2 (ja) ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
US12403175B2 (en) Methods for treating pemphigus disorders
US20240109961A1 (en) Treatment of chronic prurigo
JP7854003B2 (ja) 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
EA052304B1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТОВ FcRn ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ ГРАВИС
HK40026538A (en) Use of fcrn antagonists for treatment of generalized myasthenia gravis
EA046454B1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТОВ FcRn ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ ГРАВИС
HK40087085A (zh) 治疗天疱疮病症的方法
HK40074337B (en) Antagonists of human neonatal fc receptor (fcrn) for treating pemphigus disorders
HK40074337A (en) Antagonists of human neonatal fc receptor (fcrn) for treating pemphigus disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ARGENX BV

Free format text: FORMER NAME(S): ARGENX BVBA